

**Supplementary Table 8. Clinical outcomes stratified by LVAD implantation periods**

Variable	Pre-reimbursement period <sup>a</sup> (n = 23)	Post-reimbursement period <sup>a</sup> (n = 27)	p value
All-cause mortality during follow-up	7 (30.4)	4 (14.8)	0.184
Stroke	9 (39.1)	7 (25.9)	0.318
Driveline infection	6 (26.0)	3 (11.1)	0.270
Gastrointestinal bleeding	8 (34.7)	5 (18.5)	0.191
Major bleeding	14 (60.8)	13 (48.1)	0.368
Postop bleeding control surgery	4 (17.3)	3 (11.1)	0.689
Device malfunction	0	1 (3.7)	1.000
Postoperative RHF	8 (34.7)	3 (11.1)	0.044
Inotropic weaning failure	7 (30.4)	1 (3.7)	0.017
Inotropic restart or multidrug	1 (4.3)	3 (11.1)	0.614
RVAD insertion	4 (17.3)	0	0.038

Values are presented as number (%).

LVAD, left ventricular assist device; RHF, right heart failure; RVAD, right ventricular assist device.

<sup>a</sup>The national insurance commenced reimbursement for pre-approved cases since October, 2018.